TCGA-E9-A3Q9-01A-11R-A21T-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 33
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.330
- KRAS_SIGNALING_DN+0.270
- BILE_ACID_METABOLISM+0.220
- ESTROGEN_RESPONSE_LATE+0.210
- COAGULATION+0.190
- MYOGENESIS+0.190
- INFLAMMATORY_RESPONSE+0.170
- XENOBIOTIC_METABOLISM+0.170
- KRAS_SIGNALING_UP+0.160
- ESTROGEN_RESPONSE_EARLY+0.120
Top 10 suppressed
- MYC_TARGETS_V2-0.720
- MYC_TARGETS_V1-0.700
- E2F_TARGETS-0.660
- G2M_CHECKPOINT-0.660
- MITOTIC_SPINDLE-0.560
- UNFOLDED_PROTEIN_RESPONSE-0.510
- DNA_REPAIR-0.500
- OXIDATIVE_PHOSPHORYLATION-0.490
- PROTEIN_SECRETION-0.460
- PI3K_AKT_MTOR_SIGNALING-0.450
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.944 |
| 2 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.917 |
| 3 | sclc1020_S66.txt | — | cohortA1 | 0.913 |
| 4 | TCGA-62-8397-01A-11R-2326-07 | — | cohortA1 | 0.913 |
| 5 | BS_912NX4Y0 | Ganglioglioma | — | 0.905 |
| 6 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.901 |
| 7 | MDT-AP-0813 | Med | Medulloblastoma | 0.901 |
| 8 | MDT-AP-0208 | Med | Medulloblastoma | 0.899 |
| 9 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.893 |
| 10 | BS_AKRHBPNZ | Ganglioglioma | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.030 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |